TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05276947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: position with peanut ball
Description: The experimental group will be positioned with the peanut ball until the end of the active phase of labor.
Study: NCT05444439

Intervention type: OTHER
Group type: OTHER
Intervention: Histopathological examination endoscopic gastric biopsies:
Description: Histological sections from the antrum and body regions will be stained with Giemsa stain. Giemsa stain working solution was prepared as follows: 40 ml Giemsa stock solution with 60 ml of distilled water. Giemsa stock solution will be prepared as follows: Giemsa powder 4 g, glycerol 250 ml and methanol 250 ml. Histological sections will be examined by a gastrointestinal pathologist to standardize the classification of gastritis. Histopathological classification will be recorded as following (acute gastritis, mild-moderate- severe chronic gastritis, Glandular atrophy or Intestinal metaplasia).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Upper endoscopy
Description: it will be done patient before start empirical therapy and multiple antrum and/or corpus biopsies will be taken . Patient will be fasting at least 8 hours.Upper and findings will be recorded in the report as presence of gastroesophageal reflux disease, diffuse or localised gastric and/or duodenal redness, mucosal swelling, atrophy of mucosa, nodularity, intestinal metaplasia, erosions or ulcers.

Intervention type: DRUG
Group type: OTHER
Intervention: empirical H.pylori regimens
Description: Start empirical antibiotics regimens patient triple therapy ((levofloxacin 400 mg once , amoxicillin 1000 mg twice for 2 weeks) and (Proton pump inhibitor twice for 1 month)). Follow up after 2 weeks after finishing regimen by Stool Ag in stool

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: H.Pylori Ag in stool
Description: Any symptomatic patient is above 18 years old with H pylori infection patients diagnosed by positive H pylori Ag in stool will be included.~assessment of laboratory response, 2 weeks after finishing empirical therapy.
Study: NCT06350539

Intervention type: OTHER
Intervention: Biological Sample Collection
Description: Excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).

Intervention type: OTHER
Intervention: Biological Sample Collection
Description: Excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
Study: NCT05255029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POD T 49P implantation experimental
Description: The investigational lens will be implanted within the capsular bag after removal of the natural crystalline lens following phacoemulsification and alignment the toric axis of investigational lens to the intend axis which was calculated by the Toric calculator software. When enroll the test lenses into both eyes, the lens is implanted first to the eye with more advanced cataract. If both eyes have a similar degree of cataract, perform the surgery first for the right eye. The timing of surgery the investigational lens into the fellow eye will be determined after the investigator and the investigator (hereinafter referred to as the investigator) have confirmed the safety of the previously operated eye.
Study: NCT06160076

Intervention type: DEVICE
Intervention: Radiofrequency
Description: Patient with atrial fibrillation ablated per catheter using radiofrequency energy

Intervention type: DEVICE
Intervention: Pulsed electric field
Description: Patient with atrial fibrillation ablated per catheter using pulsed electric field
Study: NCT06136312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi4
Description: TURBT procedure performed with the Multi4 instrument in local anesthesia
Study: NCT05928572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGM initiation approach
Description: Use of a nutrition-focused approach versus a self-directed approach during CGM initiation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CGM initiation approach
Description: Use of a nutrition-focused approach versus a self-directed approach during CGM initiation
Study: NCT05392751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EA-2353
Description: EA-2353 Ophthalmic Suspension
Study: NCT05152628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus granules
Description: Oral
Study: NCT04986189

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Low dose CT thorax
Description: A low dose CT scan of the thorax to screen for lung cancer
Study: NCT05566236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: board game
Description: A board game was designed based on situated learning theory and the results of relevant studies. This board game contains a summary, answer booklet, and multiple card game tasks including situations of interpersonal interaction. The participants must discuss, share personal experiences, and find the answer together.
Study: NCT05593770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
Study: NCT05620719

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Posttraumatic Headache
Description: CBT for Posttraumatic Headaches consists of 8 sessions of cognitive behavioral therapy that focus on (1) discussions and exercises that increase awareness of what may be related to headaches, (2) relaxation techniques to manage physiological stress, and (3) problem-solving techniques to manage common stressors. Sessions are delivered weekly and can last between 45 to 75 minutes based on clinical content and patient response to the material.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants will continue to engage in medical care as usual for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine-based Cognitive Behavioral Therapy (TCBT)
Description: Participants assigned to TCBT will receive 8 sessions of cognitive behavioral therapy using telemedicine rather than face-to face office visits.
Study: NCT04974398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Arm A: Penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin 80 mg/m2, administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine 1000 mg/ m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), 3 weeks (21 days) per treatment cycle (Q3W), and then followed by penpulimab monotherapy as maintenance treatment, Q3W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Arm B: Placebo (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin (80 mg/m2, administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/m2, on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), every 3 weeks (21 days) per treatment cycle and then followed by placebo monotherapy as maintenance treatment, Q3W. Subjects in Arm B will have the opportunity to crossover to open-label treatment with penpulimab monotherapy after radiographic disease progression.
Study: NCT06642623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enavogliflozin
Description: The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin or Empagliflozin
Description: The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
Study: NCT06638801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach-led caregiver-implemented early literacy and developmental programming
Description: Caregivers will receive training about child brain development in the first 3 years of life. The training will emphasize the areas of spoken words, physical education, pointer-finger concept, focus and label, reading lessons, and mathematics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach Out and Read Training
Description: Reach Out and Read parent training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reach Out and Read Training
Description: Reach Out and Read parent training
Study: NCT06639880

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care exercise
Description: the usual care for the lumbar spine which includes TENS, ultrasound, and myofascial release for the lumbar spine in addition to a core program including bridge, half bridge and clam shell exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: triple attack protocol
Description: a modified P-A mobilization, manipulation, and stabilization program (Active and passive) for the thoracic spine in addition to the usual care and the core program for the lumbar spine
Study: NCT06641453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GPC3-CART cells
Description: Phase 1: Dose escalation (3+3): Dose 1 (1 × 10\^6 cells/kg) with or without FC regimen, Dose 2 (3 × 10\^6 cells/kg), Dose 3 (6 × 10\^6 cells/kg).~Phase 2: Dose at RP2D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate for Injection
Description: Administered intravenously at a dose of 20-30 mg/m²/day on days -5, -4, and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide for Injection
Description: Administered intravenously at a dose of 300-500 mg/m²/day on days -5, -4, and -3.
Study: NCT06644950

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Efficacy and safety of administering 1 or two cartridges of anesthesia
Description: The investigator will administer the first anesthesia for NDI block with a cartridge of 4% articaine anesthetic at 1:100,000 . At the end, an envelope containing the assignment to the experimental or control group will be opened.~In the control group, only the first anesthetic (1.8 mL of articaine 4% 1:100,000) will be injected and a second puncture will be simulated, contacting the syringe without the needle, in the same area, counting up to 30 seconds.~In the experimental group two anesthetic cartridges of articaine 4% 1:100,000 will be administered with the direct technique for the inferior alveolar nerve block.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Efficacy and safety of administering 1 or two cartridges of anesthesia
Description: The investigator will administer the first anesthesia for NDI block with a cartridge of 4% articaine anesthetic at 1:100,000 . At the end, an envelope containing the assignment to the experimental or control group will be opened.~In the control group, only the first anesthetic (1.8 mL of articaine 4% 1:100,000) will be injected and a second puncture will be simulated, contacting the syringe without the needle, in the same area, counting up to 30 seconds.~In the experimental group two anesthetic cartridges of articaine 4% 1:100,000 will be administered with the direct technique for the inferior alveolar nerve block.
Study: NCT06644027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jefcare Sterile Medical Sheets
Description: Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: Jefcare Sterile Medical Sheets and skin care regimen.

Intervention type: DEVICE
Group type: OTHER
Intervention: Molicare Premium Bed Mat
Description: Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: MoliCare Premium Bed Mats and skin care regimen.
Study: NCT06452511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: In the Metformin arm of this study, 50 overweight women with polycystic ovary syndrome (PCOS) and infertility will receive a combination treatment of Letrozole and Metformin. Letrozole, aimed at inducing ovulation, will be administered according to a specified dosage regimen, alongside Metformin, an insulin-sensitizing agent used to manage PCOS, prescribed at a specified dosage regimen. Participants will undergo regular monitoring to assess ovulation and pregnancy outcomes, involving baseline assessments of health status and fertility parameters, ongoing monitoring visits to track ovulation through ultrasound and hormone levels, and final evaluation of ovulation rates and pregnancy outcomes at the study's end. This arm seeks to determine the efficacy of Metformin as an adjunct to Letrozole in improving ovulation induction and pregnancy rates among overweight women with PCOS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pep2dia
Description: In the Pep2dia arm of this study, 50 overweight women diagnosed with polycystic ovary syndrome (PCOS) and experiencing infertility will receive a combination treatment of Letrozole and Pep2dia. Letrozole, utilized to induce ovulation, will be administered according to a specified dosage regimen, along with Pep2dia, a peptide-based therapy tailored to manage PCOS, prescribed at a specified dosage regimen. Participants will undergo regular monitoring to assess ovulation and pregnancy outcomes, involving baseline assessments of health status and fertility parameters, ongoing monitoring visits to track ovulation through ultrasound and hormone levels, and a final evaluation of ovulation rates and pregnancy outcomes at the conclusion of the study period. This arm seeks to ascertain the effectiveness of Pep2dia as an adjunct to Letrozole in enhancing ovulation induction and pregnancy rates among overweight women with PCOS.
Study: NCT05516472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microbial Transplant Therapy
Description: Participants will take microbial capsules, 2 capsules daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microbial Transplant Therapy
Description: Participants will take microbial capsules, 2 capsules daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take placebo capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take placebo capsules
Study: NCT04948073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic neuromuscular stabilization approach
Description: The experimental group will follow a DNS exercise protocol based on previous procedure for a whole period of 6 weeks (three 50-min sessions per week) in addition the conventional treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Patients from both groups will receive a conventional 6-week treatment programme (18 treatment sessions, three a week, for 30-40min duration).
Study: NCT05981456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient safety competency
Description: Investigation of the effect of patient safety education given with the flipped education model and traditional education model on the competence levels of the students.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patient safety competency
Description: Investigation of the effect of patient safety education given with the flipped education model and traditional education model on the competence levels of the students.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: satisfaction with the training method
Description: Investigation of the effect of patient safety education given with the flipped education model and traditional education model on the satisfaction levels of the students from the education methods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: satisfaction with the training method
Description: Investigation of the effect of patient safety education given with the flipped education model and traditional education model on the satisfaction levels of the students from the education methods.
Study: NCT06329869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Sacituzumab govitecan, 10 mg/kg intravenous infusion (the first infusion is to be administered over 3 hours; subsequent infusions may be administered over 1 to 2 hours if previous infusions were well tolerated) on day 1 and 8 of 21-day cycle.
Study: NCT05523297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octaplex
Description: Prothrombin complex concentrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Frozen Plasma Product, Human
Description: If additional treatment is required after the maximum dose of IMP is administered or the treatment period has elapsed, patients in both groups will receive frozen plasma
Study: NCT06279520

Intervention type: DEVICE
Group type: OTHER
Intervention: VR Driving Simulator
Description: Evaluation of usual road driving abilities and assessment of response capabilities in accident-prone situations through a VR driving simulator

Intervention type: OTHER
Group type: OTHER
Intervention: Computerized Neurocognitive Function Test
Description: Evaluation of cognitive levels including attention and memory (the Trail Making Test, Digit Span Test, Auditory (or Visual) Continuous Performance Test , and Card Sorting)

Intervention type: OTHER
Group type: OTHER
Intervention: Driver Test Station
Description: Conducting qualified tests of a person's basic physical driving ability including steering, acceleration and braking, using Driver Test Station(Autoadapt AB, Stenkullen, Sweden)

Intervention type: OTHER
Group type: OTHER
Intervention: On-road field driving Test
Description: Researchers and driver's license supervisors ride in the driver's license test vehicle to evaluate the subject's actual driving ability. the validity of the VR simulator by comparing the results of the VR simulator with the actual vehicle driving ability.
Study: NCT05391802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair
Description: Transcatheter mitral valve repair (TMVr) is a minimally invasive procedure. Doctors place a thin tube (calleda catheter) into a large vein to reach your heart. A clip is then placed onto the center of your mitral valve. The valve continues to open and close, allowing blood to flow through while reducing MR.
Study: NCT05420532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: A video game-based physical activity training applied using a commercial game console.
Study: NCT06501118

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: 1. Standardized materials to discuss the rationale and procedural aspects of the intervention, including details on the specific oxygen target-related modifications to the mechanical ventilation order-set prior to starting the intervention phase.~2. Virtual respiratory therapist (vRT) - directed real-time feedback on adherence to the SpO2 target range as a part of the mechanical ventilation order-set embedded in UCHealth EHR (EPIC).
Study: NCT04671628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxing music
Description: Participants will be asked to listen to relaxing music for 30 minutes each day. They will allowed to choose between several playlists based on their preference.
Study: NCT06317025

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-modal Intelligent Anesthesia Monitoring System
Description: To evaluate the sensitivity and specificity of self-developed anesthesia monitoring systems in diagnosing the depth of anesthesia (too deep or too shallow)
Study: NCT04107649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephonic Active Coaching (Motivational Interviewing) + Financial Incentives
Description: As part of TAC(MI)+FI, participants speak with a health coach at Brigham and Women's Hospital once a week via telephone for weeks 6-13 following surgery, and once every other week for weeks 14-31 after surgery. Participants in this arm can receive financial rewards for achieving weekly physical activity goals, as well as bonus rewards for achieving goals multiple weeks in a row. Over the course of this 6-month long TAC(MI)+FI intervention period, these participants are able to receive up to $680 for meeting physical activity goals, and up to $95 in bonus rewards.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wrist based activity tracker wear
Description: Activity tracking data will be collected on a weekly basis. Participants who receive this intervention are eligible to be entered into a lottery to win one of two $25 rewards for every week they wear their wrist-based activity tracker \>10 hours for \>4/7 days a week, beginning 6-weeks after surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wrist based activity tracker wear
Description: Activity tracking data will be collected on a weekly basis. Participants who receive this intervention are eligible to be entered into a lottery to win one of two $25 rewards for every week they wear their wrist-based activity tracker \>10 hours for \>4/7 days a week, beginning 6-weeks after surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: Basic Study Activities
Description: Basic study activities begin two-weeks before TKR and end approximately 24-months after TKR. Basic study activities include: two in-person visits at the local clinic site (2 weeks before TKR and 32-weeks after TKR), having check-in calls with study staff weekly from weeks 1-13 after surgery and every other week for weeks 14-31, completing 6 surveys, and wearing an ActiGraph activity tracker (waist-worn) for five one-week periods throughout the study (2-weeks before-TKR, 32-weeks post-TKR, one-year post-TKR, 18-months post-TKR, two-years post-TKR). All participants will be eligible to receive up to $235 for completing these activities over the course of two years.